Research-use-only educational overview. This article is not medical advice, not a recommendation to use, take, or buy any compound, and none of the peptides discussed are approved to build muscle in healthy people.
Search “best peptides for muscle growth” and you get ranked lists that read like shopping guides. That framing is misleading. In this article, “best” means only most studied and most discussed in the context of muscle and growth-hormone biology — not proven to work, not safe for everyone, and not something anyone should read as personalized advice. Being the most-researched compound in a category is very different from having clinical proof that it grows muscle in a healthy adult like you.
Below is an honest map of six peptides most often named in this conversation: what the peer-reviewed literature (indexed in PubMed) actually shows for muscle specifically, and — just as important — where the evidence is thin, animal-only, or absent. Each is graded on an evidence tier so the gap between a human randomized trial, a mouse study, and an anecdote is visible.
Comparison at a glance
| Peptide | What it’s studied for (re: muscle) | Evidence tier | Key caveat |
|---|---|---|---|
| MK-677 (ibutamoren) | Ghrelin-receptor agonist; raises GH/IGF-1; increased fat-free mass in a 2-year RCT | Moderate (human RCT) | No gain in strength or function; raised fasting glucose, lowered insulin sensitivity |
| Sermorelin | GHRH analog; raises IGF-1; small lean-mass rise (men only) in a related-analog trial | Weak human | Tiny studies; no effect in women; muscle outcome minimal |
| CJC-1295 | Long-acting GHRH analog; sustained rise in GH/IGF-1 in healthy adults | Indirect only | Human trial measured hormones, not muscle mass or strength |
| Ipamorelin | Selective GH secretagogue (MK-677-like mechanism) | Preclinical / none | No human muscle-growth trial; human use studied mainly for gut motility |
| IGF-1 LR3 | Long-acting IGF-1 analog; muscle hypertrophy in animal overexpression models | Animal / preclinical | No human trials; systemic IGF-1 signaling carries theoretical risk |
| Follistatin-344 | Myostatin antagonist; large muscle gains in animals | Preclinical peptide; human data only via gene therapy | Human benefit shown only with AAV gene therapy in disease, not the injectable peptide |
MK-677 (ibutamoren)
MK-677 is an orally active ghrelin-receptor agonist that raises growth hormone (GH) and IGF-1, and it has the strongest human data of this group. In a 2-year randomized, placebo-controlled trial of 65 healthy older adults, 25 mg daily raised GH and IGF-1 into the young-adult range and increased fat-free mass by about 1.1 kg versus a 0.5 kg loss on placebo. Crucially, the authors reported that this extra fat-free mass did not translate into any gain in strength or physical function, and MK-677 also increased appetite, raised fasting glucose, and reduced insulin sensitivity (Nass et al., 2008). So the honest read is “measurable body-composition change, unproven performance benefit, real metabolic trade-offs.” For how it is characterized in research settings, see the MK-677 dosage reference.
Sermorelin
Sermorelin is a growth-hormone-releasing hormone (GHRH 1-29) analog that prompts the pituitary to release its own GH. In a small 16-week randomized trial of a closely related GHRH analog in older adults, treatment raised IGF-1 and increased lean body mass — but only in men, not women, and the sample was tiny (Khorram et al., 1997). A separate retrospective chart review of a GH-secretagogue/sermorelin combination raised average IGF-1 from roughly 160 to 239 ng/mL, but measured hormones rather than muscle (Sigalos et al., 2017). The evidence linking sermorelin to actual muscle growth is therefore weak and indirect. See the sermorelin dosage reference.
CJC-1295
CJC-1295 is a long-acting GHRH analog. In healthy adults, subcutaneous CJC-1295 produced sustained, dose-dependent increases in GH (roughly 2- to 10-fold) and IGF-1 for days to weeks (Teichman et al., 2006). The important caveat: that trial measured hormone levels and safety, not muscle mass, strength, or body composition — so there is no direct human evidence that CJC-1295 builds muscle. It is a pharmacology result, not a muscle-growth result. See the CJC-1295 dosage reference.
Ipamorelin
Ipamorelin is a selective GH secretagogue in the same mechanistic family as MK-677, but it lacks MK-677’s body-composition trial. Its documented human development was largely in gastrointestinal motility (for example, post-operative ileus), and its GH-releasing effect is characterized mainly in preclinical work. No controlled human trial has tested ipamorelin for muscle growth, so any muscle claim is extrapolation from mechanism and anecdote, not clinical evidence. See the ipamorelin dosage reference.
IGF-1 LR3
IGF-1 LR3 is a long-acting laboratory analog of IGF-1. There are no human trials of IGF-1 LR3 for muscle growth; it is primarily used as a cell-culture reagent. The supporting science is preclinical: viral overexpression of IGF-1 in mouse muscle produced hypertrophy and greater strength, partly through satellite-cell activation (Barton-Davis et al., 1999). Animal hypertrophy does not establish that injected IGF-1 LR3 is effective or safe in people, and broad systemic IGF-1 signaling carries theoretical risks. See the IGF-1 LR3 dosage reference.
Follistatin (Follistatin-344)
Follistatin antagonizes myostatin, a natural brake on muscle growth, and in animals follistatin can dramatically increase muscle mass. The only human muscle data comes from gene therapy, not the injectable peptide: an AAV1-delivered follistatin (FS344) trial in sporadic inclusion-body myositis improved 6-minute walk distance (+56 m/year versus −25.8 m/year in untreated matched patients) in a small, non-blinded study (Mendell et al., 2017). Reviews also note that several anti-myostatin drugs showed limited efficacy in trials (Mariot et al., 2017). There is essentially no controlled human evidence that injectable follistatin peptide builds muscle in healthy people. See the follistatin-344 dosage reference.
What the evidence actually supports
Honest bottom line: none of these six has robust clinical proof that it builds functional muscle in healthy adults.
- Best-evidenced (still limited): MK-677 is the only one with a multi-year human RCT showing a fat-free-mass increase — but that gain did not improve strength or function, and it worsened glucose control.
- Weak / indirect human data: sermorelin and CJC-1295 reliably raise GH and IGF-1 in people, but raising a hormone is not the same as growing muscle; the muscle-specific outcomes are small, inconsistent, or simply not measured.
- Preclinical or anecdotal only: ipamorelin, IGF-1 LR3, and injectable follistatin have no controlled human muscle-growth trials. Their reputation rests on mechanism, animal studies, or gene-therapy work in disease — not on evidence that they work, or are safe, for physique goals.
Important limitations
- Every compound here is sold and discussed for research use only. Most are not approved by any regulator for muscle growth, and several are prohibited in competitive sport.
- “Most studied” is not “proven for you.” Individual results, long-term safety, product purity, and interactions are unknown, and some carry documented downsides (for example, MK-677’s effect on blood glucose).
- This overview summarizes published research; it is not medical advice and not a recommendation to use, take, or buy anything. Decisions about your health belong with a qualified healthcare professional who knows your history.
- If you are comparing figures for study or reference purposes only, our peptide dosage calculator is an educational tool, not a prescription.
FAQ
What is the single best peptide for muscle growth?
There isn’t one with strong proof. Of the commonly named options, MK-677 has the most human data, but even its randomized trial found increased fat-free mass without any measured gain in strength or function — so “best studied” still falls short of “proven to build usable muscle.”
Do peptides that raise GH or IGF-1 automatically build muscle?
No. Compounds like CJC-1295 and sermorelin clearly raise GH and IGF-1 in humans, but the trials that show those hormone changes did not demonstrate meaningful muscle growth. Elevated hormones are a mechanism, not a guaranteed outcome.
Are any of these approved or safe for bodybuilding?
No. None is approved for muscle building in healthy people, several are banned in competition, and safety data for this purpose are limited or absent. They are research compounds, and any decision about them is a matter for a qualified clinician, not a website.
Sources
Concrete claims above are drawn from peer-reviewed literature indexed in PubMed:
- Nass R, et al. Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults. Ann Intern Med. 2008. doi:10.7326/0003-4819-149-9-200811040-00003 (PMID 18981485)
- Teichman SL, et al. Prolonged stimulation of GH and IGF-1 secretion by CJC-1295. J Clin Endocrinol Metab. 2006. doi:10.1210/jc.2005-1536 (PMID 16352683)
- Khorram O, et al. Endocrine and metabolic effects of long-term administration of a GHRH analog in age-advanced men and women. J Clin Endocrinol Metab. 1997. doi:10.1210/jcem.82.5.3943 (PMID 9141536)
- Sigalos JT, et al. Growth hormone secretagogue treatment in hypogonadal men raises serum IGF-1 levels. Am J Mens Health. 2017. doi:10.1177/1557988317718662 (PMID 28830317)
- Barton-Davis ER, Shoturma DI, Sweeney HL. Contribution of satellite cells to IGF-I induced hypertrophy of skeletal muscle. Acta Physiol Scand. 1999. doi:10.1046/j.1365-201x.1999.00618.x (PMID 10632630)
- Mendell JR, et al. Follistatin gene therapy for sporadic inclusion body myositis improves functional outcomes. Mol Ther. 2017. doi:10.1016/j.ymthe.2017.02.015 (PMID 28279643)
- Mariot V, et al. Downregulation of myostatin pathway in neuromuscular diseases may explain challenges of anti-myostatin therapeutic approaches. Nat Commun. 2017. doi:10.1038/s41467-017-01486-4 (PMID 29192144)
- Cardaci TD, et al. LGD-4033 and MK-677 use impacts body composition and biomarkers: a case report. Exp Physiol. 2022. doi:10.1113/EP090741 (PMID 36303408)
